5AM Venture Management’s Dianthus Therapeutics DNTH Stock Holding History

5AM Venture Management’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-365,053	Closed	-$14.4M	–	24
2025 Q3	$14.4M	Sell	365,053 -619,672	-63%	-$15.8M	5.26%	9
2025 Q2	$18.3M	Sell	984,725 -42,986	-4%	-$806K	7.05%	3
2025 Q1	$18.6M	Hold	1,027,711	–	–	7.05%	3
2024 Q4	$22.4M	Sell	1,027,711 -203,908	-17%	-$5.24M	5.35%	6
2024 Q3	$33.7M	Sell	1,231,619 -1,346	-0.1%	-$37.5K	6.97%	5
2024 Q2	$31.9M	Sell	1,232,965 -9,064	-0.7%	-$218K	7.14%	4
2024 Q1	$37.3M	Sell	1,242,029 -230,235	-16%	-$5M	8.34%	3
2023 Q4	$15.3M	Hold	1,472,264	–	–	4.06%	8
2023 Q3	$20.1M	Buy	+1,472,264	New	+$18.5M	5.79%	4

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

5AM Venture Management's DNTH Position: Q4 2025 in Review

5AM Venture Management sold out of Dianthus Therapeutics (DNTH) in Q4 2025, closing a stake of 365,053 shares — an estimated $14.4M sold.

5AM Venture Management first reported a position in DNTH in Q3 2023 and held it in 9 quarters. The position peaked at $37.3M in Q1 2024. 165 funds tracked by Wall St. Rank hold DNTH as of Q4 2025.

5AM Venture Management reported no remaining Dianthus Therapeutics position as of Q4 2025 after selling out during the quarter.
5AM Venture Management sold 365,053 Dianthus Therapeutics shares in Q4 2025, an estimated $14.4M.
5AM Venture Management first reported a position in Dianthus Therapeutics in Q3 2023 and held it in 9 quarters.
5AM Venture Management's Dianthus Therapeutics position peaked at $37.3M in Q1 2024.
165 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2025.

Based on 5AM Venture Management's 13F filing for Q4 2025, filed 17 Feb 2026.